Innovation Pharmaceuticals Inc.

$ Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000147793223008688 Filed on November 20, 2023

Income Statement

Concept	2023 Q3

Balance Sheet

Concept	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$864.0K
YoY Change	-70.89%
Cash & Equivalents	$864.0K
Short-Term Investments
Other Short-Term Assets	$76.00K
YoY Change	-37.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$940.0K
YoY Change	-69.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.742M
YoY Change	-5.19%
Other Assets	$78.00K
YoY Change	0.0%
Total Long-Term Assets	$5.727M
YoY Change	-8.34%
TOTAL ASSETS
Total Short-Term Assets	$940.0K
Total Long-Term Assets	$5.727M
Total Assets	$6.667M
YoY Change	-28.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.021M
YoY Change	3.57%
Accrued Expenses	$192.0K
YoY Change	113.33%
Deferred Revenue
YoY Change
Short-Term Debt	$238.0K
YoY Change	-2.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.048M
YoY Change	-1.62%
LONG-TERM LIABILITIES
Long-Term Debt	$457.0K
YoY Change	-41.86%
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$457.0K
YoY Change	-41.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.048M
Total Long-Term Liabilities	$457.0K
Total Liabilities	$5.505M
YoY Change	-6.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$126.2M
YoY Change	2.12%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.254M
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	$1.162M
YoY Change
Total Liabilities & Shareholders Equity	$6.667M
YoY Change	-28.6%

Cashflow Statement

Concept	2023 Q3

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	ipix	Convertible Preferred Stock Liability Shares Issued ConvertiblePreferredStockLiabilitySharesIssued	360	shares
CY2023Q3	ipix	Related Party Accruals RelatedPartyAccruals	42000	usd
CY2023Q2	ipix	Related Party Accruals RelatedPartyAccruals	24000	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1514000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	ipix	Cash Flow From Operations CashFlowFromOperations	-700000	usd
CY2023Q3	ipix	Working Capital WorkingCapital	-4100000	usd
CY2023Q3	us-gaap	Cash Cash	900000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5000000.0	usd
CY2023Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of patent costs and other long-lived assets and amortizable intangible assets, valuation of equity grants and income tax valuation. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
CY2023Q3	ipix	Net Loss Per Shares Basics And Diluted NetLossPerSharesBasicsAndDiluted	-0.00
CY2022Q3	ipix	Net Loss Per Shares Basics And Diluted NetLossPerSharesBasicsAndDiluted	-0.00
CY2023Q3	ipix	Total Weighted Average Shares Outstanding TotalWeightedAverageSharesOutstanding	518347691	shares
CY2022Q3	ipix	Total Weighted Average Shares Outstanding TotalWeightedAverageSharesOutstanding	503964459	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7778269	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8268269	shares
CY2023Q3	ipix	Stock Options Arising From Convertible Note Payable And Accrued Interest StockOptionsArisingFromConvertibleNotePayableAndAccruedInterest	519636	shares
CY2022Q3	ipix	Stock Options Arising From Convertible Note Payable And Accrued Interest StockOptionsArisingFromConvertibleNotePayableAndAccruedInterest	508448	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	0	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	58392	shares
CY2023Q3	ipix	Convertible Preferred Stock Excluded From Computation Of Earnings Per Share Amount ConvertiblePreferredStockExcludedFromComputationOfEarningsPerShareAmount	35571821	shares
CY2022Q3	ipix	Convertible Preferred Stock Excluded From Computation Of Earnings Per Share Amount ConvertiblePreferredStockExcludedFromComputationOfEarningsPerShareAmount	36000000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43869726	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44835109	shares
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	93000	usd
CY2023Q3	ipix	Accrued Research And Development Consulting Fees AccruedResearchAndDevelopmentConsultingFees	150000	usd
CY2023Q2	ipix	Accrued Research And Development Consulting Fees AccruedResearchAndDevelopmentConsultingFees	49000	usd
CY2023Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	8000	usd
CY2023Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	8000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	22000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	16000	usd
CY2023Q3	ipix	Accrued Salary Current AccruedSalaryCurrent	192000	usd
CY2023Q2	ipix	Accrued Salary Current AccruedSalaryCurrent	73000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1443000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1543000	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	71000	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	71000	usd
CY2023Q3	ipix	Withholding Tax Related Parties WithholdingTaxRelatedParties	73000	usd
CY2023Q2	ipix	Withholding Tax Related Parties WithholdingTaxRelatedParties	76000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1587000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1690000	usd
CY2023Q3	ipix	Operating Lease Cost Included In General And Administrative In The Companys Consolidated Statement Of Operations OperatingLeaseCostIncludedInGeneralAndAdministrativeInTheCompanysConsolidatedStatementOfOperations	1000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	3000	usd
CY2023Q3	ipix	Total Operating Cost TotalOperatingCost	4000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	55000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.18	pure
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	13000	usd
CY2023Q3	us-gaap	Contractual Obligation ContractualObligation	500000	usd
CY2023Q3	ipix	Accrued Interest Related Party Amount AccruedInterestRelatedPartyAmount	22000	usd
CY2022Q2	ipix	Accrued Interest Related Party Amount AccruedInterestRelatedPartyAmount	16000	usd
CY2023Q3	ipix	Outstanding Balance Of Principal And Interest OutstandingBalanceOfPrincipalAndInterest	260000	usd
CY2022Q2	ipix	Outstanding Balance Of Principal And Interest OutstandingBalanceOfPrincipalAndInterest	229000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	178000	usd
CY2023Q3	ipix	Redeem Preferred Stock RedeemPreferredStock	1.20	pure
CY2022Q3	us-gaap	Dividends Dividends	8000	usd
CY2023Q3	ipix	Accrued Dividends AccruedDividends	10000	usd
CY2022Q3	ipix	Accrued Dividends AccruedDividends	5000	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	1080	usd
CY2023Q2	ipix	Convertible Preferred Stock Liability Shares Issued ConvertiblePreferredStockLiabilitySharesIssued	360	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Other Assets OtherAssets	2077000	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	1985000	usd
CY2023Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001355250
CY2023Q3	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	ipix	Convertible Preferred Stock Liability Shares Outstanding ConvertiblePreferredStockLiabilitySharesOutstanding	360	shares
CY2023Q2	ipix	Convertible Preferred Stock Liability Shares Outstanding ConvertiblePreferredStockLiabilitySharesOutstanding	360	shares
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	1080	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	ipix	Treasury Stock Common Stock TreasuryStockCommonStock	10874593	shares
CY2023Q3	ipix	Fair Value Ending Balance FairValueEndingBalance	457000	usd
CY2023Q3	dei	Document Type DocumentType	10-Q
CY2023Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	dei	Entity File Number EntityFileNumber	001-37357
CY2023Q3	dei	Entity Registrant Name EntityRegistrantName	INNOVATION PHARMACEUTICALS INC.
CY2023Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0565645
CY2023Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	301 Edgewater Place
CY2023Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Wakefield
CY2023Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01880
CY2023Q3	dei	City Area Code CityAreaCode	978
CY2023Q3	dei	Local Phone Number LocalPhoneNumber	921-4125
CY2023Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	864000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1518000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	76000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	116000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	940000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	1634000	usd
CY2023Q3	us-gaap	Other Investments OtherInvestments	3742000	usd
CY2023Q2	us-gaap	Other Investments OtherInvestments	3806000	usd
CY2023Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1907000	usd
CY2023Q2	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1999000	usd
CY2023Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	usd
CY2023Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	78000	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	78000	usd
CY2023Q3	us-gaap	Assets Assets	6667000	usd
CY2023Q2	us-gaap	Assets Assets	7517000	usd
CY2023Q3	ipix	Accounts Payable AccountsPayable	1511000	usd
CY2023Q2	ipix	Accounts Payable AccountsPayable	1511000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3021000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2985000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	192000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73000	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1613000	usd
CY2023Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1587000	usd
CY2023Q2	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1690000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55000	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	238000	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	213000	usd
CY2023Q3	ipix	Accrued Dividend Series B Five Convertibles Preferred Stock AccruedDividendSeriesBFiveConvertiblesPreferredStock	10000	usd
CY2023Q2	ipix	Accrued Dividend Series B Five Convertibles Preferred Stock AccruedDividendSeriesBFiveConvertiblesPreferredStock	5000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5048000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5021000	usd
CY2023Q3	ipix	Series B5 Convertible Preferred Stock Liability Series B5 Convertible Preferred Stock Liability SeriesB5ConvertiblePreferredStockLiabilitySeriesB5ConvertiblePreferredStockLiability	457000	usd
CY2023Q2	ipix	Series B5 Convertible Preferred Stock Liability Series B5 Convertible Preferred Stock Liability SeriesB5ConvertiblePreferredStockLiabilitySeriesB5ConvertiblePreferredStockLiability	457000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5505000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	5478000	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129569000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129566000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-126205000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125325000	usd
CY2023Q3	ipix	Treasury Stock Common Stock TreasuryStockCommonStock	10874593	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2254000	usd
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2254000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1162000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2039000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6667000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7517000	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
CY2022Q3	us-gaap	Revenues Revenues	0	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	281000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	869000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	133000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	291000	usd
CY2023Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	118000	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	118000	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	270000	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	104000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	802000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1382000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	64000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	31000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-31000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-866000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1413000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	9000	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	7000	usd
CY2023Q3	ipix	Interest Expense Related Parties InterestExpenseRelatedParties	5000	usd
CY2022Q3	ipix	Interest Expense Related Parties InterestExpenseRelatedParties	8000	usd
CY2023Q3	us-gaap	Other Expenses OtherExpenses	14000	usd
CY2022Q3	us-gaap	Other Expenses OtherExpenses	15000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-880000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1428000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-880000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1428000	usd
CY2023Q3	ipix	Basic And Diluted Net Loss Per Share BasicAndDilutedNetLossPerShare	-0.00
CY2022Q3	ipix	Basic And Diluted Net Loss Per Share BasicAndDilutedNetLossPerShare	-0.00
CY2023Q3	ipix	Basic And Diluted Weighted Average Number Of Common Shares BasicAndDilutedWeightedAverageNumberOfCommonShares	518347691	shares
CY2022Q3	ipix	Basic And Diluted Weighted Average Number Of Common Shares BasicAndDilutedWeightedAverageNumberOfCommonShares	503964459	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	4730000	usd
CY2022Q3	ipix	Stok Issued During Period For Offering Cost StokIssuedDuringPeriodForOfferingCost	-59000	usd
CY2022Q3	ipix	Restricted Common Stock Award Issued To Employee For Services Amount RestrictedCommonStockAwardIssuedToEmployeeForServicesAmount	1000	usd
CY2022Q3	ipix	Stock Options Issued To Employee For Services Amount StockOptionsIssuedToEmployeeForServicesAmount	28000	usd
CY2022Q3	ipix	Stock Options Issued To Consultants For Services Amount StockOptionsIssuedToConsultantsForServicesAmount	2000	usd
CY2022Q3	ipix	Stock Options Issued To Director For Services Amount StockOptionsIssuedToDirectorForServicesAmount	147000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1428000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3421000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2039000	usd
CY2023Q3	ipix	Shares Issued To Employee For Services SharesIssuedToEmployeeForServices	1000	usd
CY2023Q3	ipix	Stock Options Issued To Employee For Services Amount StockOptionsIssuedToEmployeeForServicesAmount	2000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-880000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1162000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-880000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1428000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	178000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	93000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	64000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	31000	usd
CY2023Q3	ipix	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	40000	usd
CY2022Q3	ipix	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	23000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	36000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	350000	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	119000	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2000	usd
CY2023Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-103000	usd
CY2022Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	10000	usd
CY2023Q3	ipix	Increase Decrease In Accrued Dividend IncreaseDecreaseInAccruedDividend	5000	usd
CY2022Q3	ipix	Increase Decrease In Accrued Dividend IncreaseDecreaseInAccruedDividend	0	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55000	usd
CY2022Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-46000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-677000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-791000	usd
CY2023Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000	usd
CY2022Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000	usd
CY2023Q3	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	25000	usd
CY2022Q3	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-6000	usd
CY2023Q3	ipix	Dividend Paid To Preferred Stockholders DividendPaidToPreferredStockholders	0	usd
CY2022Q3	ipix	Dividend Paid To Preferred Stockholders DividendPaidToPreferredStockholders	-38000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-44000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-654000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-839000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1518000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3807000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	864000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2968000	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	15000	usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q3	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. Basis of Presentation and Nature of Operations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Unaudited Interim Financial Information</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited condensed consolidated financial statements of Innovation Pharmaceuticals Inc. have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive consolidated financial statements and should be read in conjunction with our audited financial statements for the year ended June 30, 2023, included in our Annual Report on Form 10-K for the year ended June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the opinion of the management of Innovation Pharmaceuticals Inc., all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms “Company,” “Innovation,” “we,” “us” or “our” mean Innovation Pharmaceuticals Inc.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Basis of Presentation </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Innovation Pharmaceuticals Inc. was incorporated on August 1, 2005 in the State of Nevada. Effective June 5, 2017, the Company amended its Articles of Incorporation and changed its name from Cellceutix Corporation to Innovation Pharmaceuticals Inc. On February 15, 2019, the Company formed IPIX Pharma Limited (“IPIX Pharma”), a wholly-owned subsidiary incorporated under the Companies Act 2014 of Ireland. IPIX Pharma is a Private Company Limited by Shares. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a clinical stage biopharmaceutical company. The Company’s common stock is quoted on the OTC Pink, symbol “IPIX.”</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Basis of Consolidation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These condensed consolidated financial statements include the accounts of Innovation Pharmaceuticals Inc., a Nevada corporation, and our wholly-owned subsidiary, IPIX Pharma, an Ireland limited company. All significant intercompany transactions and balances have been eliminated in consolidation. There was no translation gain and loss for the three months ended September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Nature of Operations - Overview</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are in the business of developing or licensing innovative small molecule therapies. Our strategy is to maximize the value of our drug compound Brilacidin. The Company also acquired a non-controlling interest in BT BeaMedical Technologies Ltd. (“BTL”), formerly known as Squalus Medical Ltd., a private company developing a novel image guided surgical laser platform. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We currently own all development and marketing rights to our products, other than the license rights granted to Alfasigma S.p.A. in July 2019 for the development, manufacturing and commercialization of locally-administered Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis (“UP/UPS”). In order to successfully develop and market our products, we may have to partner with additional companies. Prospective partners may require that we grant them significant development and/or commercialization rights in return for agreeing to share the risk of development and/or commercialization.</p>
CY2023Q3	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-900000	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10874593	shares
CY2023Q3	ipix	Total Patents Cost TotalPatentsCost	5434000	usd
CY2023Q2	ipix	Total Patents Cost TotalPatentsCost	5432000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3527000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3433000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1907000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1999000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94000	usd
CY2023Q3	ipix	Accrued Director Fees AccruedDirectorFees	12000	usd
CY2023Q2	ipix	Accrued Director Fees AccruedDirectorFees	0	usd
CY2023Q3	ipix	Advance Convertible Debt AdvanceConvertibleDebt	25000	usd
CY2023Q3	ipix	Repaid Additionalconvertible Debt RepaidAdditionalconvertibleDebt	6000	usd
CY2023Q3	ipix	Exclusive License Agreement Disclosure Textblock ExclusiveLicenseAgreementDisclosureTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8. Exclusive License Agreement and Patent Assignment Agreement</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 18, 2019, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of UP/UPS.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the terms of the License Agreement, Alfasigma made an initial upfront non-refundable payment of $0.4 million to the Company in July, 2019 and will make additional payments of up to $24.0 million to the Company based upon the achievement of certain milestones, including a $1.0 million payment due following commencement of the first Phase 3 clinical trial of Brilacidin for UP/UPS and an additional $1.0 million payment upon the filing of a marketing approval application with the U.S. Food and Drug Administration or the European Medicines Agency. At this time, Alfasigma has completed Phase 1 clinical research with Brilacidin. In addition to the milestones, Alfasigma will pay a royalty to the Company equal to six percent of net sales of Brilacidin for UP/UPS, subject to adjustment as provided in the License Agreement. The Company received an initial upfront non-refundable payment of $0.4 million and reported as revenue in July, 2019 and the Company did not receive any further milestone payment during the three months ended September 30, 2023 and 2022. The Company recently learned that Alfasigma is considering terminating further work under the License Agreement, although as of the date of this report, Alfasigma has not notified the Company of the termination of the License Agreement or a cessation of further work under the License Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 13, 2022, the Company entered a Patent Assignment Agreement with Fox Chase Chemical Diversity Center, Inc. (“FCCDC”), pursuant to which the Company assigned the title, rights and interest in and to the applications of certain patents in accordance with an earlier collaborative research agreement related to antifungal drug discovery work to which the Company had rights. On May 3, 2022, the Company received payment of $18,000 from FCCDC based on FCCDC’s third-party license of broad-spectrum anti-fungals and a separate agreement between the Company and FCCDC. On January 18, 2023, the Company was notified by FCCDC that its third-party license with Basilea Pharmaceutica for development of broad-spectrum antifungals was terminated by the licensee. </p>
CY2023Q3	ipix	Operating Lease Weighted Average Remaining Lease Terms OperatingLeaseWeightedAverageRemainingLeaseTerms	P0Y
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	4000	usd
CY2023	ipix	Expected Dividend Yield ExpectedDividendYield	0.05	pure
CY2023	ipix	Expected Stock Price Volatility ExpectedStockPriceVolatility	0.60	pure
CY2023	ipix	Risk Free Interest Rate RiskFreeInterestRate	0.0292	pure
CY2023	ipix	Stock Price StockPrice	0.03
CY2023	ipix	Proceeds From Warrant Exercises1 ProceedsFromWarrantExercises1	982.5
CY2023Q3	ipix	Schedule Of Reconciliation Of The Company Tabletextblock ScheduleOfReconciliationOfTheCompanyTabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FY 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance, June 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">786,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Conversion of Series B-2 preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(329,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Change in fair value of Series B-2 preferred stock </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">—</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance, June 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">457,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Conversion of Series B-2 preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">—</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Change in fair value of Series B-2 preferred stock </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">—</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance, September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">457,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q3	ipix	Fair Value Beginning Balance FairValueBeginningBalance	786000	usd
CY2022Q3	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	329000	usd
CY2022Q3	ipix	Change In Fair Value Of Series B2 Preferred Stock ChangeInFairValueOfSeriesB2PreferredStock	0	usd
CY2023Q3	ipix	Fair Value Beginning Balance FairValueBeginningBalance	457000	usd
CY2023Q3	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	0	usd
CY2023Q3	ipix	Change In Fair Value Of Series B2 Preferred Stock ChangeInFairValueOfSeriesB2PreferredStock	0	usd
CY2022Q3	ipix	Fair Value Ending Balance FairValueEndingBalance	457000	usd
CY2023Q3	ipix	Accrued Dividend Percentage Rate AccruedDividendPercentageRate	0.05	pure
CY2023Q3	us-gaap	Dividends Dividends	5000	usd

Files In Submission

Name	View Source	Status
0001477932-23-008688-index-headers.html	Edgar Link	pending
0001477932-23-008688-index.html	Edgar Link	pending
0001477932-23-008688.txt	Edgar Link	pending
0001477932-23-008688-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ipix-20230930.xsd	Edgar Link	pending
ipix_10q.htm	Edgar Link	pending
ipix_ex311.htm	Edgar Link	pending
ipix_ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ipix-20230930_cal.xml	Edgar Link	unprocessable
ipix-20230930_def.xml	Edgar Link	unprocessable
ipix-20230930_lab.xml	Edgar Link	unprocessable
ipix-20230930_pre.xml	Edgar Link	unprocessable
ipix_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Innovation Pharmaceuticals Inc.

2023 Q3 Form 10-Q Financial Statement

#000147793223008688 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission